BioNTech SE Sponsored ADR $BNTX Shares Sold by Carmignac Gestion

Key Points

• Carmignac Gestion cut its BioNTech stake by 29.1% in the second quarter, selling 32,836 shares and retaining 79,875 shares valued at approximately $7.45 million. Institutional investors own 15.52% of BNTX.
• BioNTech CEO Ugur Sahin sold 31,500 shares for about $3.26 million under a pre-arranged Rule 10b5-1 trading plan, reducing his position by 3.87%.
• BNTX shares fell 4.9% to $98.66 after the company reported a quarterly loss and revenue of $122.31 million, missing analyst expectations. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $126.

Carmignac Gestion lowered its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 29.1% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 79,875 shares of the company's stock after selling 32,836 shares during the quarter. Carmignac Gestion's holdings in BioNTech were worth $7,448,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BNTX. Larson Financial Group LLC grew its stake in shares of BioNTech by 86.4% in the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company's stock worth $26,000 after purchasing an additional 127 shares during the last quarter. EFG International AG acquired a new position in BioNTech in the fourth quarter worth approximately $29,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of BioNTech by 520.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company's stock valued at $30,000 after buying an additional 260 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of BioNTech by 118.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company's stock worth $60,000 after acquiring an additional 305 shares in the last quarter. Finally, Vestcor Inc acquired a new position in shares of BioNTech in the 4th quarter worth $153,000. 15.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling at BioNTech

In other news, CEO Ugur Sahin sold 31,500 shares of the stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $103.52, for a total transaction of $3,260,880.00. Following the transaction, the chief executive officer owned 781,709 shares of the company's stock, valued at approximately $80,922,515.68. This represents a 3.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have recently commented on BNTX shares. UBS Group raised BioNTech from a "neutral" rating to a "buy" rating and upped their target price for the company from $117.00 to $135.00 in a report on Wednesday, May 27th. Sanford C. Bernstein reissued a "market perform" rating on shares of BioNTech in a research note on Friday, June 5th. Morgan Stanley cut their price objective on BioNTech from $126.00 to $119.00 and set an "overweight" rating on the stock in a report on Wednesday, July 8th. Berenberg Bank reduced their price objective on shares of BioNTech from $155.00 to $140.00 and set a "buy" rating for the company in a research note on Tuesday, May 12th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of BioNTech in a report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, BioNTech currently has a consensus rating of "Moderate Buy" and an average target price of $126.00.

BioNTech Stock Down 4.9%

Shares of NASDAQ BNTX traded down $5.10 during mid-day trading on Tuesday, reaching $98.66. The company had a trading volume of 1,127,241 shares, compared to its average volume of 1,114,558. BioNTech SE Sponsored ADR has a twelve month low of $79.52 and a twelve month high of $124.00. The stock's 50 day moving average is $96.82 and its 200-day moving average is $95.61. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. The stock has a market capitalization of $24.95 billion, a PE ratio of -12.60 and a beta of 1.29.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The firm had revenue of $122.31 million during the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company's quarterly revenue was down 59.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.60) EPS. As a group, equities analysts anticipate that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current fiscal year.

About BioNTech

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.